Ani Pharmaceuticals (ANIP) Change in Receivables (2012 - 2026)

Ani Pharmaceuticals has disclosed Change in Receivables across 15 years of filings, most recently posting -$25.5 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$25.5 million, down 1332.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.8 million (up 287.95% YoY), and the FY2025 annual result was $58.5 million, up 177.56% from the prior year.
• Change in Receivables came in at -$25.5 million for Q1 2026 at Ani Pharmaceuticals, down from $27.9 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $27.9 million in Q4 2025 to a low of -$25.5 million in Q1 2026.
• The 5-year median for Change in Receivables is $5.5 million (2025), against an average of $5.2 million.
• Across the five-year window, Change in Receivables surged 2333.29% in 2022 and slumped 1332.55% in 2026, its largest moves.
• Ani Pharmaceuticals' Change in Receivables stood at $25.0 million in 2022, then sank by 167.04% to -$16.8 million in 2023, then jumped by 252.2% to $25.5 million in 2024, then rose by 9.18% to $27.9 million in 2025, then tumbled by 191.64% to -$25.5 million in 2026.
• The last three Change in Receivables figures came in at -$25.5 million (Q1 2026), $27.9 million (Q4 2025), and $27.0 million (Q3 2025), per Business Quant data.